Committed to patients with this serious hematologic disease
Beta thalassemia is a genetic blood disorder marked by an erythroid maturation defect resulting in the inability to produce red blood cells that develop properly. Red blood cells are critical for tasks such as delivering oxygen to cells throughout the body. In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body. Affected individuals also have a shortage of red blood cells (anemia), which can cause pale skin, weakness, fatigue, and more serious complications such as enlarged livers and spleens. People with beta thalassemia are at an increased risk of developing abnormal blood clots. Beta thalassemia is a occurs most frequently in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, and Southeast Asia.1
Celgene has a rich heritage in discovering and developing therapies for serious blood disorders and cancers and is committed, alongside its partner Acceleron Pharma, Inc., to an investigational program for patients in this important area.
Advocacy & Collaboration
Learn about patient organizations supporting patients with Thalassemia:
Cooley’s Anemia Foundation – http://www.thalassemia.org/
Thalassemia International Federation – http://thalassaemia.org.cy/
Learn more about our partner Acceleron Pharma, Inc.:
Celgene currently has an investigational therapy in clinical studies for patients with beta-thalassemia.
Visit ResearchOncology.com to learn more about the latest research in beta thalassemia